Fig. 1 · Structure

Documents & Downloads

Oridonin (Isodonol)

Cat. No. A10675 CAS 28957-04-2

CFTR Inhibitor

Oridonin (Isodonol), an entkaurane diterpenoid isolated from Rabdosia rubescens, is an important traditional Chinese herbal remedy.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Akt1 IC50 8.4 μM
Akt2 IC50 8.9 μM

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 > 10 μM Cytotoxicity against human A549 cells after 48 hrs by MTT assay [PMID: 23819871]
A549 IC50 13.45 μM Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay [PMID: 31494472]
A549 IC50 17.8 μM Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 31202992]
A549 IC50 18.15 μM Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 30921757]
A549 IC50 30.4 μM Antiproliferative activity against human A549 cells incubated for 72 hrs by CCK8 cells [PMID: 31200238]
Bel-7402 IC50 5.41 μM Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay [PMID: 28165738]
Bel-7402 IC50 7.85 μM Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 30921757]
Bel-7402 IC50 8.31 μM Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 31202992]
Bel-7402 IC50 9.59 μM Antiproliferative activity against human Bel7402 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 30981113]
BEL-7404 tumor cell line IC50 17.92 μM Antiproliferative activity against human Bel7404 cells after 48 hrs by MTT assay [PMID: 28165738]
DU-4475 IC50 16.95 μM Antiproliferative activity against human DU4475 cells after 72 hrs by MTT assay [PMID: 32610904]
H22 IC50 4.88 μM Antiproliferative activity against mouse H22 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay [PMID: 35121201]
HCC1806 IC50 21.74 μM Antiproliferative activity against human HCC1806 cells after 72 hrs by MTT assay [PMID: 32610904]
HCC1937 IC50 8.27 μM Antiproliferative activity against human HCC1937 cells after 72 hrs by MTT assay [PMID: 32610904]
HCT-116 IC50 6.84 μM Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 30981113]
HeLa IC50 17.28 μM Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay [PMID: 35121201]
HepG2 IC50 8.12 μM Antiproliferative activity against human HepG2 cells incubated for 72 hrs by CCK8 cells [PMID: 31200238]
HL-60 IC50 2.5 μM Cytotoxicity against human HL60 cells after 48 hrs by MTT assay [PMID: 23819871]
HL-60 IC50 9.46 μM Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 30921757]
K562 IC50 4.32 μM Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay [PMID: 35121201]

20 records · Scroll to view more

Oridonin (Isodonol) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Oridonin (Isodonol) from 3 published references. In vitro models include MG-63; primary peritoneal macrophages from ApoE−/− mice.

Oridonin (Isodonol) In Vitro Studies

In MG-63 cells incubated with Oridonin for 24 h, the cell viability IC50 was 12.29 ± 1.02 μM. In primary peritoneal macrophages from ApoE−/− mice, Oridonin decreased ox-LDL-induced lipid deposition compared with cultures without Oridonin. In K562 cells, Oridonin at 20 μM for 2 h substantially inhibited BCR-ABL activity. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cell viability in MG-63 cells

Cell-based study · MG-63 [1]

After 24 h of treatment, the IC50 (the concentration of drug inhibiting 50% of cells) value of MG-63 cells was 12.29 ± 1.02 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viabilityIC50 MG-63, 24 h: IC50 = 12.29 ± 1.02 μM[1]

Literature-Reported Treatment Conditions

Exposure duration
24 h
Method
incubation with oridonin
Reported limits
Not stated in the sentences used: dose, vehicle.
Methods and source locations

Compound reported in the paper: Oridonin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Oridonin induced apoptosis in human osteosarcoma cells (S2, S3); Materials and methods > MTT assay (S135); Materials and methods > Statistical analysis (S180)

cell viability: cell viability; comparator: untreated controls — Results > Oridonin induced apoptosis in human osteosarcoma cells (S2, S3)

Oridonin decreases lipid deposition in primary peritoneal macrophages

Cell-based study · primary peritoneal macrophages from ApoE−/− mice [2]

Primary peritoneal macrophages from ApoE−/− mice were cultured with Oridonin at 2.5 μM and 5 μM for 48 h and compared with cultures without Oridonin. Oil red O staining showed that Oridonin decreased ox-LDL-induced lipid deposition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Oil red O stainingReported result oridonin decreased ox-LDL-induced lipid deposition in peritoneal macrophages[2]

Literature-Reported Treatment Conditions

Treatment concentration
2.5 μM and 5 μM
Exposure duration
48 h
Method
cultured
Co-treatment
Other interventions in this design: human oxidized low-density lipoprotein (ox-LDL) 50 μg/mL; BBL thioglycollate, Brewer modified 1 mL 4%. Compound effect isolated by the comparison: with or without oridonin.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Oridonin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Isolation of peritoneal macrophages (S23, S26); Results > Oridonin inhibits lipid uptake and enhances lipid efflux in macrophages in vivo and in vitro (S112, S113)

Oil red O staining: Oil red O staining; comparator: without oridonin — Results > Oridonin inhibits lipid uptake and enhances lipid efflux in macrophages in vivo and in vitro (S113)

Oridonin inhibits BCR-ABL activity in K562 cells

Cell-based study · K562 cells [3]

K562 cells were treated with Oridonin at 20 μM for 2 h, with DMSO as the control. Oridonin substantially inhibited BCR-ABL activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
BCR-ABL/C-ABL activityReported result the activity of BCR-ABL was substantially inhibited by oridonin in K562 cells[3]

Literature-Reported Treatment Conditions

Treatment concentration
20 μM
Exposure duration
2 h
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Oridonin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Oridonin induces rapid depletion of the BCR-ABL fusion protein (S3); Materials and Methods > Cell lines and reagents (S66); Figure 1 legend (S133, S134)

BCR-ABL/C-ABL activity: BCR-ABL/C-ABL activity; comparator: DMSO (Ctrl) — Results > Oridonin induces rapid depletion of the BCR-ABL fusion protein (S3); Figure 1 legend (S134)

Oridonin (Isodonol) In Vivo Studies

BALB/c nude mice bearing HL60/p210WT and HL60/p210T315I xenografts received Oridonin intraperitoneally at 15 mg/kg or vehicle. Oridonin substantially inhibited growth of both WT BCR-ABL and imatinib-resistant T315I-BCR-ABL xenograft tumors. [3]

Oridonin inhibits xenograft tumor growth

Animal study · 5-week-old BALB/c nude mouse; HL60/p210WT cells over the right shoulder and HL60/p210T315I cells over the left shoulder; 6 mice/group [3]

BALB/c nude mice bearing HL60/p210WT and HL60/p210T315I xenografts received Oridonin intraperitoneally at 15 mg/kg or vehicle. Oridonin substantially inhibited growth of both WT BCR-ABL and imatinib-resistant T315I-BCR-ABL xenograft tumors.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
tumor volumesReported result oridonin substantially inhibited not only the growth of xenograft tumors with WT BCR-ABL but also those with imatinib-resistant T315I-BCR-ABL[3]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
once a day for 12 consecutive days
Vehicle
2% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Oridonin 15 mg/kgvehicle (2% DMSO)oridonin substantially inhibited not only the growth of xenograft tumors with WT BCR-ABL but also those with imatinib-resistant T315I-BCR-ABL[3]
Oridonin 15 mg/kg
Model: 5-week-old BALB/c nude mouse; HL60/p210WT cells over the right shoulder and HL60/p210T315I cells over the left shoulder; 6 mice/group
Methods and source locations

Compound reported in the paper: Oridonin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Oridonin triggers degradation of imatinib-resistant BCR-ABL and exhibits inhibitory effects in vitro and in vivo (S61); Materials and Methods > Xenograft tumor models (S123, S124); Figure 6 legend (S193)

tumor volumes: tumor volumes; comparator: vehicle (2% DMSO) — Results > Oridonin triggers degradation of imatinib-resistant BCR-ABL and exhibits inhibitory effects in vitro and in vivo (S61); Figure 6 legend (S193)

Oridonin 15 mg/kg · Results > Oridonin triggers degradation of imatinib-resistant BCR-ABL and exhibits inhibitory effects in vitro and in vivo (S61); Materials and Methods > Xenograft tumor models (S124)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 28957-04-2
Applications CFTR Inhibitor
Formula C20H28O6
Molecular Weight 364.4
Synonyms Isodonol
SMILES
C=C1C(=O)[C@]23[C@H](O)[C@H]1CC[C@H]2[C@@]12CO[C@]3(O)[C@@H](O)[C@@H]1C(C)(C)CC[C@@H]2O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 69 mg/mL (189.33 mM)
Water Insoluble
Ethanol 27 mg/mL (74.09 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
11.8 mg/mL
Vehicle
5% DMSO+20%PEG 300+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Oridonin (Isodonol) Research References

  1. [1] Lu Y, Sun Y, Zhu J, et al. Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway. Cell Death Dis (2018). PMID: 29323103 DOI: 10.1038/s41419-017-0031-6 Source material
  2. [2] Wang L, Zhao X, Ding J, et al. Oridonin attenuates the progression of atherosclerosis by inhibiting NLRP3 and activating Nrf2 in apolipoprotein E-deficient mice. Inflammopharmacology (2023). PMID: 37155118 DOI: 10.1007/s10787-023-01161-9 Source material
  3. [3] Huang H, Weng H, Dong B, et al. Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia. Sci Rep (2017). PMID: 28128329 DOI: 10.1038/srep41525 Source material

Added to your cart

View Cart Checkout
Loading...